Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ch. Egarter is active.

Publication


Featured researches published by Ch. Egarter.


Maturitas | 1996

Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints.

Ch. Egarter; Johannes C. Huber; R. Leikermoser; R. Haidbauer; H. Pusch; F. Fischl; M. Putz

OBJECTIVE Tibolone has been shown to alleviate climacteric symptoms. This study was designed to compare the effect of tibolone (Livial, 2.5 mg daily) on different climacteric complaints and its impact on the endometrium, determined by vaginal ultrasound, with that of conjugated estrogens (Premarin, 0.625 mg daily) continuously for 6 months in combination with the progestogen medrogestone (Colpron, 2 x 5 mg daily for 12 days each month). METHODS One hundred and twenty-nine postmenopausal women were recruited and the severity of climacteric symptoms as well as endometrial thickness were recorded at the pre-trial examination and after 1, 3, and 6 months. RESULTS With the exception of vertigo, mood depression, mood disorder, loss of libido, and dryness of skin, where tibolone was found to be more effective than conjugated estrogens/medrogestone, climacteric symptoms improved significantly in both groups over the 6-month study period. Endometrial thickness did not increase significantly in the tibolone group, whereas in the conjugated estrogens/medrogestone group there was a highly significant increase after 1 month and still a trend towards significance after 6 months. Recurrence of vaginal bleeding occurred significantly less frequently in the tibolone group than in the comparison group. CONCLUSION Tibolone seems to offer a complete treatment of the climacteric complaints whilst avoiding some of the problems associated with classical hormone replacement therapy.


Contraception | 1995

Ovarian function during low-dose oral contraceptive use

Ch. Egarter; M. Putz; Heinz Strohmer; P. Speiser; R. Wenzl; Johannes C. Huber

Lowering the total steroid dose in modern oral contraceptives (OCs) has been connected with a higher incidence of ovarian follicle and cyst formation. To investigate the presence of ovarian follicles and cysts by means of vaginal ultrasonography and serum hormone determinations during use of two low-dose OCs, 65 volunteers were randomized to receive either 20 micrograms ethinylestradiol (EE) + 150 micrograms desogestrel (group A) or 35 micrograms EE + 250 micrograms norgestimate (group B) for a 2-month study period. At baseline, 39% of women in group A and 31% in group B exhibited at least one follicle < 35 mm in diameter. By the end of the second treatment cycle, the frequency of these follicles had decreased to 14% in each group. Only one subject in the higher estrogen group developed an ovarian cyst > 35 mm. One subject in each group demonstrated hormone levels characteristic of ovulation; no pregnancy occurred in either group. The 20 micrograms EE preparation was not found to lead more often to ovarian follicles or cysts when compared with a 35 micrograms EE preparation, possibly because of the type and dose of the progestogen used.


Placenta | 1997

Hypoxia downregulates continuous and interleukin-1-induced expression of human chorionic gonadotropin in choriocarcinoma cells.

Heinz Strohmer; Herbert Kiss; B. Mo¨sl; Ch. Egarter; Peter Husslein; M. Kno¨fler

The effects of hypoxia on JEG-3, BeWo, and JAr cells were investigated and it was demonstrated that choriocarcinoma cells can be used as a model to study the molecular mechanism of hypoxia-mediated repression of human chorionic gonadotropin (hCG). Cells were maintained under hypoxia (3.5 per cent O2) for 72 h without loss of variability, as demonstrated by the fact that 93-98 per cent of the cells excluded trypan blue. Up to 48 h, cell growth was not significantly influenced by hypoxia, and analysis by flow cytometry did not reveal major changes in cell cycle distribution. JEG-3, BeWo, and JAr cells which were grown for 48 h under hypoxia secreted 81, 67, and 71 per cent less hCG than cells cultivated under normoxic conditions. The extent of hCG reduction was dependent on the oxygen concentration. Moreover, release of the hormone from hypoxic JAr cells was not stimulated upon addition of interleukin-1 (IL-1). Treatment of JEG-3 cells with methotrexate (MTX) led to a 4.3-fold augmentation in hCG secretion and to an increase in the amount of G0/G1 cells. However, when cells were cultured in the presence of MTX and hypoxia, hCG secretion decreased 10-fold and beta hCG mRNA declined to almost undetectable levels suggesting that downregulation of beta hCG mRNA is the major cause of diminished hCG release under hypoxic conditions.


Prostaglandins Leukotrienes and Essential Fatty Acids | 1991

Prostaglandin versus expectant management in early tubal pregnancy

Ch. Egarter; H. Kiss; Peter Husslein

Since ectopic pregnancy may terminate in spontaneous recovery we compared treatment by means of prostaglandin (PG) application with expectant management in laparoscopically verified tubal gestations. Twelve patients received local and systemic PG, 4 patients were treated with sodium chloride and in 7 patients laparoscopy was discontinued without medical therapy. The comparison between the PG group and the placebo groups revealed a highly significant difference with regard to a subsequent necessary surgical intervention and hospitalisation. Expectant management may only be recommended in very selected cases, whereas PG treatment seems to produce favourable results in cases of early tubal pregnancy.


Prostaglandins Leukotrienes and Essential Fatty Acids | 1989

Treatment of ectopic pregnancy by means of prostaglandins

Ch. Egarter; Peter Husslein

A new conservative method of terminating ectopic pregnancies is described. A high degree of success was achieved by administering PG F2alpha by laparoscopy and PG E2 analogue systemically.


Maturitas | 1988

β-endorphin levels during the climacteric period

Brigitte Schurz; G. Wimmer-Greinecker; M. Metka; G. Heytmanek; Ch. Egarter; W. Knogler

Abstract Hot flushes are not caused by hypergonadotrophinaemia. This is apparent because peaks of gonadotrophin in the serum do not coincide with cutaneously measured hot flushes while such flushes still occur in hypophysectomized women. Gonadotrophin-releasing hormone and other neurotransmitters (possibly β-endorphin) affect thermoregulation. The following hypothesis is advanced. During the climacteric period neurotransmitter changes, a decrease in catechol oestrogens, a decrease in α-2-adrenoceptor activity and cessation of ovarian steroid production may lead to alterations in endogenous opiate activity and thus to disturbances of thermoregulation, resulting in the occurrence of hot flushes. Low β-endorphin levels in the peripheral plasma, which rise again following oestrogen treatment, are observed during the climacteric. On the other hand, women with severe hot flushes caused by a stress event show enormously increased β-endorphin values, which are normalized by hormone substitution therapy acting via still unknown neuroendocrinological feedback mechanisms.


Archives of Gynecology and Obstetrics | 1992

Reproductive performance after local and systemic prostaglandin for ectopic pregnancy.

Ch. Egarter; Herbert Kiss; N. Vavra; Peter Husslein

SummaryThe injection of different substances into early, unruptured tubal pregnancies is increasingly advocated. In this study, fertility was evaluated after treatment of tubal pregnancy by means of prostaglandins. The overall tubal patency rate was 86.4% and 14 of 20 patients (70%) could subsequently achieve pregnancy.


Archives of Gynecology and Obstetrics | 1988

Prophylactic perioperative use of clindamycin and metronidazole in vaginal hysterectomy without pelvic floor repair

Ch. Egarter; R. Fitz; R. Brehm; Peter Husslein

SummaryWe studied the effect of perioperative clindamycin (3×600 mg in 100 ml 0.9% saline), metronidazole (3×500 mg in 100 ml 0.9% saline) and a placebo (3×100 ml of 0.9% saline) in 120 patients having a vaginal hysterectomy without colporrhaphy. The rate of postoperative urinary tract infections was significantly higher in the placebo group, but there was no significant difference between the three groups in the days of postoperative fever (a temperature above 37°C) or in the length of hospital stay. One patient on placebo had a vault infection and another had a fever of unknown origin.


Archives of Gynecology and Obstetrics | 1995

Unsuccessful treatment of tubal pregnancy by shock wave lithotripsy

Ch. Egarter; J. Hofbauer; D. Bikas; K. Reisenberger

A tubal pregnancy was unsuccessfully treated by means of a lithotrypter.


Archives of Gynecology and Obstetrics | 1989

A new method of treating tubal pregnancy using prostaglandin F2a and E2

Ch. Egarter; R. Fitz; Peter Husslein

The present paper reports on the treatment of 30 tubal pregnancies verified by laparoscopy by means of intratubal prostaglandin (PG) F2a and systemic PG E2. Tubal pregnancy was successfully treated in 25 patients; three patients exhibited side effects. The comparison with surgical management showed better results concerning the tubal patency in the PG-treated group. Further studies should clarify whether this technically simple procedure is superior to the existing methods.SummaryThe present paper reports on the treatment of 30 tubal pregnancies verified by laparoscopy by means of intratubal prostaglandin (PG) F2a and systemic PG E2. Tubal pregnancy was successfully treated in 25 patients; three patients exhibited side effects. The comparison with surgical management showed better results concerning the tubal patency in the PG-treated group. Further studies should clarify whether this technically simple procedure is superior to the existing methods.ZusammenfassungIn dieser Studie wird über die Erfolge der Therapie von Eileiterschwangerschaften mit Prostaglandin (PG) F2a und PG E2 bei 30 Patientinnen berichtet. Nur 5 Patientinnen mußten einer anschließenden operativen Therapie unterzogen werden; 3 Patientinnen wiesen systemische Nebenwirkungen auf. Der Vergleich mit herkömmlicher chirurgischer Therapie bezüglich der späteren Durchgängigkeit der betreffenden Tuben fiel stark zugunsten der PG behandelten Gruppe aus. Das technisch einfache Prozedere sollte durch weitere Vergleiche gegenüber der bisherigen Behandlungsmethode abgeklärt werden.

Collaboration


Dive into the Ch. Egarter's collaboration.

Top Co-Authors

Avatar

Peter Husslein

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Herbert Kiss

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Beck

University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G.W. Hacker

University of Salzburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge